'Cv safety' presentation slideshows

569 views • 48 slides

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus. DPP-4 Inhibitor CV Outcomes Trials in T2DM. T2DM CV Outcomes Trials From the DPP-4 Inhibitor Class. SAVOR-TIMI 53: Primary Endpoint. SAVOR-TIMI 53: Hospitalization for HF. EXAMINE: Primary Endpoint. EXAMINE: Hospitalization for HF.

642 views • 46 slides

Canagliflozin Cardiovascular Safety

Canagliflozin Cardiovascular Safety. Potential CV protection pathways of SGLT2i. Diab Vasc Dis Res. 2015 Mar;12(2):90-100. Effect of Canagliflozin on potential CV risk factors.

109 views • 10 slides